文献速递血栓与止血

静脉血栓栓塞症相关死亡风险:系统综述与贝叶斯Meta分析

Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis.
PubMed 文献 · Lancet Haematol · 2020-01-01

该系统综述与贝叶斯Meta分析纳入86项静脉血栓栓塞症预防随机对照试验,其中52项阳性试验(逾7万例患者)显示对照组静脉血栓栓塞症风险显著高于治疗组(RR 2.74)。静脉血栓栓塞症预防对全因死亡率的影响为零(对照组9.8% vs 治疗组9.8%,RR 1.01),但对照组肺栓塞和致死性肺栓塞更多、大出血更少。

要点

  • 静脉血栓栓塞症预防对全因死亡率无因果效应(RR 1.01,95% CrI 0.97-1.06)。
  • 对照组肺栓塞(RR 2.22)和致死性肺栓塞(RR 1.58)均多于治疗组。
  • 对照组大出血少于治疗组(RR 0.60,95% CrI 0.47-0.75)。

核心结论

  • 鉴于静脉血栓栓塞症预防对死亡率的影响为零,认为静脉血栓栓塞症是常见死亡原因的观念应予以修正。
  • 研究结果对静脉血栓栓塞症预防试验中使用复合终点提出质疑,并为降阶治疗试验提供依据。

研究设计与样本

  • 系统综述与贝叶斯Meta分析,检索MEDLINE、Embase、PubMed和Web of Science,检索时间从1993年1月1日至2018年3月19日。
  • 纳入静脉血栓栓塞症风险升高、随机分配至抗凝或抗血小板治疗 versus 安慰剂或无治疗的患者研究。
  • 排除使用活性对照药物的研究以及死亡率数据不可用的研究。
  • 从4229项筛选中确定86项符合条件的随机对照试验,其中52项为阳性试验,数据来自逾7万例患者。
  • 主要终点为全因死亡率,次要终点为肺栓塞、致死性肺栓塞和大出血;分析聚焦于报告预防对静脉血栓栓塞症终点有统计学显著效应的研究。

主要发现

  • 52项阳性试验中,对照组静脉血栓栓塞症风险显著高于治疗组(RR 2.74,95% CrI 2.32-3.31,p<0.0001)。
  • 静脉血栓栓塞症预防对死亡率无因果效应:对照组死亡3391/34537例(9.8%),治疗组死亡3498/35795例(9.8%),RR 1.01(95% CrI 0.97-1.06,p=0.58),异质性低(τ 0.02,95% CrI 0.00-0.07,p=0.89)。
  • 对照组肺栓塞多于治疗组(RR 2.22,95% CrI 1.78-2.89,p<0.0001)。
  • 对照组致死性肺栓塞多于治疗组(RR 1.58,95% CrI 1.14-2.19,p=0.01)。
  • 对照组大出血少于治疗组(RR 0.60,95% CrI 0.47-0.75,p<0.0001);加入34项阴性研究后除致死性肺栓塞效应证据较弱(RR 1.42,95% CrI 1.05-1.91,p=0.02)外,其余终点结果相似。

关键数值与推荐

  • 静脉血栓栓塞症预防对全因死亡率无因果效应(RR 1.01,95% CrI 0.97-1.06,p=0.58)。
  • 对照组静脉血栓栓塞症风险为治疗组的2.74倍(RR 2.74,95% CrI 2.32-3.31,p<0.0001)。
  • 对照组肺栓塞风险为治疗组的2.22倍(RR 2.22,95% CrI 1.78-2.89,p<0.0001),致死性肺栓塞风险为治疗组的1.58倍(RR 1.58,95% CrI 1.14-2.19,p=0.01)。
  • 对照组大出血风险为治疗组的0.60倍(RR 0.60,95% CrI 0.47-0.75,p<0.0001)。
  • 加入34项阴性研究后,致死性肺栓塞效应证据较弱(RR 1.42,95% CrI 1.05-1.91,p=0.02)。

临床怎么用

  • 作者认为,鉴于静脉血栓栓塞症预防对死亡率的影响为零,认为静脉血栓栓塞症是常见死亡原因的观念应予以修正。
  • 作者认为,研究结果对静脉血栓栓塞症预防试验中使用复合终点提出质疑,并为降阶治疗试验提供依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism is associated with increased mortality risk in some populations, but how frequently it is a direct cause of death is unclear. We used data from venous thromboembolism prevention trials to evaluate the causal effect of venous thromboembolism reduction on mortality. METHODS: We did a systematic review and meta-analysis of randomised controlled trials (RCTs) evaluating venous thromboembolism prevention. We searched MEDLINE, Embase, PubMed, and Web of Science starting from Jan 1, 1993, to March 19, 2018. We included studies of patients who were at elevated risk of venous thromboembolism and were randomly assigned to either anticoagulant or antiplatelet therapy versus placebo or no treatment. We excluded studies with an active control agent (which might mitigate the lethality of venous thromboembolism) and those for which mortality data were unavailable. We modelled heterogeneity in a Bayesian framework, taking overall mortality as a primary endpoint, and pulmonary embolism, fatal pulmonary embolism, and major bleeding as secondary endpoints. We focused our analyses on studies reporting statistically significant effects of prevention on venous thromboembolism endpoints. We report treatment effects as median risk ratios (RRs), wherein a null effect equals 1, with 95% credible intervals (CrIs). This meta-analysis was registered with PROSPERO, CRD42018089697. FINDINGS: From 4229 studies screened, we identified 86 eligible RCTs; 52, with data from over 70 000 patients, were positive, with significantly increased venous thromboembolism risk in patients in control groups versus treatment groups (RR 2·74, 95% CrI 2·32-3·31, p<0·0001). The meta-analysis established that the causal effect of venous thromboembolism prevention on mortality was null (control group mortality was 3391 [9·8%] of 34 537 patients; treatment group mortality was 3498 [9·8%] of 35 795 patients [RR 1·01, 95% CrI 0·97-1·06; p=0·58]) with low heterogeneity (τ 0·02, 95% CrI 0·00-0·07, p=0·89). Patients in control groups had more pulmonary embolism (RR 2·22, 95% CrI 1·78-2·89, p<0·0001) and fatal pulmonary embolism (1·58, 1·14-2·19, p=0·01), but less major bleeding (0·60, 0·47-0·75, p<0·0001) than those in treatment groups. A meta-analysis with the additional 34 negative studies yielded similar results for all endpoints except fatal pulmonary embolism, where evidence of an effect was weaker (1·42, 1·05-1·91, p=0·02). INTERPRETATION: The perception that venous thromboembolism is a common cause of mortality should be revised considering the null effect of venous thromboembolism prevention on mortality. Our findings call into question the use of composite endpoints in venous thromboembolism-prevention trials and provide rationale for de-escalation trials. FUNDING: None.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Klemen ND, Feingold PL, Hashimoto B, et al. Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis. Lancet Haematol. 2020. PMID: 32735837. doi:10.1016/S2352-3026(20)30211-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。